Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study

• Main Authors: Joaquina C. Baranda (Author), Debbie Robbrecht (Author), Ryan Sullivan (Author), Bernard Doger (Author), Armando Santoro (Author), Minal Barve (Author), Jean‐Jacques Grob (Author), Oliver Bechter (Author), Maria Vieito (Author), Maria Jose deMiguel (Author), Dirk Schadendorf (Author), Melissa Johnson (Author), Clemence Pouzin (Author), Cathy Cantalloube (Author), Rui Wang (Author), Jooyun Lee (Author), Xiaofei Chen (Author), Brigitte Demers (Author), Amele Amrate (Author), Giovanni Abbadessa (Author), F. Stephen Hodi (Author)
• Format: Book
• Published: Wiley, 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract SAR439459 (SAR'459), a "second‐generation" human anti‐transforming growth factor beta (TGFβ) monoclonal antibody, enhances the activity of immune checkpoint inhibitors. In this phase I/Ib study, we evaluated the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor a...